Search hospitals
>
Minnesota
>
Saint Paul
Regions Hospital Cancer Care Center
Claim this profile
Saint Paul, Minnesota 55101
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Solid Tumors
Conducts research for Lymphoma
Conducts research for Melanoma
141 reported clinical trials
2 medical researchers
Summary
Regions Hospital Cancer Care Center is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Solid Tumors, Lymphoma, Melanoma and other specialties. Regions Hospital Cancer Care Center is involved with conducting 141 clinical trials across 190 conditions. There are 2 research doctors associated with this hospital, such as Arkadiusz Dudek, MD and Richard A. Peterson.
Area of expertise
Breast Cancer
Regions Hospital Cancer Care Center has run 37 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Regions Hospital Cancer Care Center has run 24 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Arkadiusz Dudek, MD
Regions Cancer Care Center
5 years of reported clinical research
Richard A. Peterson
Park Nicollet Clinic - Saint Louis Park
3 years of reported clinical research
Clinical Trials running at Regions Hospital Cancer Care Center
Cancer
Lung Cancer
Brain Tumor
Meningioma
Breast Cancer
Head and Neck Cancers
Endometrial Cancer
Cervical Cancer
Kidney Cancer
Stomach Cancer
TTX-080 +/− Cetuximab/Pembrolizumab
for Cancer
This trial tests TTX-080, a new drug, alone and with other cancer drugs in patients with hard-to-treat cancers. It works by helping the immune system find and attack cancer cells.
Recruiting
1 award
Phase 1
4 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting
1 award
Phase 1 & 2
7 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Regions Hospital Cancer Care Center?
Regions Hospital Cancer Care Center is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Solid Tumors, Lymphoma, Melanoma and other specialties. Regions Hospital Cancer Care Center is involved with conducting 141 clinical trials across 190 conditions. There are 2 research doctors associated with this hospital, such as Arkadiusz Dudek, MD and Richard A. Peterson.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.